Last reviewed · How we verify
NCT06045780
HO-1/CREB3 Modulates Golgi Stress in Patients With Sepsis
trial testing nothing in Sepsis in 150 participants. Currently enrolling.
15 September 2024
Quick facts
| Lead sponsor | Tianjin Nankai Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 15 September 2023 |
| Primary completion | 15 September 2024 |
| Estimated completion | 15 November 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- nothing
Conditions studied
- Sepsis — all drugs for Sepsis →
Sponsor
Tianjin Nankai Hospital
Who can join
Adults 18 to 100, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was an ambispective observational cohort study that included sepsis patients hospitalized in the Intensive care unit (ICU) of the Nankai Hospital. All patients met the consensus criteria of sepsis-3. The purpose of this study is to investigate the valuable biomarkers for the severity of sepsis and predictors of 30-day mortality for patients with sepsis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06045780
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of nothing
Trials testing the same drug.
- NCT05830422 — Prediction of Delayed Cognitive Impairment in Cardiac Arrest Survivors With Good Neurological Outcomes · enrolling by invitation
- NCT05579353 — The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer · recruiting
- NCT05503056 — Art Therapy in Obstetric Patients · NA · completed
- NCT07205510 — Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE) · recruiting
Other recruiting trials for Sepsis
Currently open trials in the same condition.
- NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
- NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
Other Tianjin Nankai Hospital trials
Trials by the same sponsor.
- NCT06006325 — Electroacupuncture Modulates SPMs Metabolism and Respiratory Symptoms in Patients With Sepsis Complicating ARDS · NA · unknown
- NCT05172531 — Efficacy and Safety Profile of Cisatracurium Besylate for IAH · NA · unknown
- NCT05476029 — Changes of Exosomes and Biomarkers in Plasma and Alveolar Lavage Fluid of Patients With Sepsis Complicated With ARDS · unknown
- NCT05171699 — Effect of Electroacupuncture in Patients With Sepsis Associated Brain Injury · NA · unknown
- NCT04969068 — The Median Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06045780 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Nankai Hospital
- Last refreshed: 30 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06045780.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing